Annovis Bio’s Phase 3 Alzheimer’s trial gets second safety panel recommendation to continue unchanged
ANVS•Annovis Bio said an independent safety board recommended a second time that its Phase 3 DUET-AD trial of buntanetap continue without modification. Six-month topline results are expected in March 2027.
1. Trial to continue
The recommendation followed a review of safety data through September 22, 2026, and covers the once-daily investigational pill for early Alzheimer’s disease. The six-month treatment period is expected to end December 31, 2026, with database lock scheduled for February 8, 2027; results will include symptomatic findings and detailed safety outcomes.




